As-CATH4 and 5, two vertebrate-derived natural host defense peptides, enhance the immuno-resistance efficiency against bacterial infections in Chinese mitten crab, Eriocheir sinensis

2017 ◽  
Vol 71 ◽  
pp. 202-209 ◽  
Author(s):  
Zhilai Guo ◽  
Xue Qiao ◽  
Ruomei Cheng ◽  
Nannan Shi ◽  
Aili Wang ◽  
...  
2011 ◽  
Vol 55 (6) ◽  
pp. 3058-3062 ◽  
Author(s):  
Rinki Kapoor ◽  
Patrick R. Eimerman ◽  
Jonathan W. Hardy ◽  
Jeffrey D. Cirillo ◽  
Christopher H. Contag ◽  
...  

ABSTRACTTuberculosis is a leading cause of death worldwide. Resistance ofMycobacteriumto antibiotics can make treatments less effective in some cases. We tested selected oligopeptoids—previously reported as mimics of natural host defense peptides—for activity againstMycobacterium tuberculosisand assessed their cytotoxicity. A tetrameric, alkylated, cationic peptoid (1-C134mer) was most potent againstM. tuberculosisand least cytotoxic, whereas an unalkylated analogue, peptoid 14mer, was inactive. Peptoid 1-C134merthus merits further study as a potential antituberculosis drug.


2021 ◽  
Vol 22 (20) ◽  
pp. 11172
Author(s):  
Matthew Drayton ◽  
Julia P. Deisinger ◽  
Kevin C. Ludwig ◽  
Nigare Raheem ◽  
Anna Müller ◽  
...  

The rapid rise of multidrug-resistant (MDR) bacteria has once again caused bacterial infections to become a global health concern. Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), offer a viable solution to these pathogens due to their diverse mechanisms of actions, which include direct killing as well as immunomodulatory properties (e.g., anti-inflammatory activity). HDPs may hence provide a more robust treatment of bacterial infections. In this review, the advent of and the mechanisms that lead to antibiotic resistance will be described. HDP mechanisms of antibacterial and immunomodulatory action will be presented, with specific examples of how the HDP aurein 2.2 and a few of its derivatives, namely peptide 73 and cG4L73, function. Finally, resistance that may arise from a broader use of HDPs in a clinical setting and methods to improve biocompatibility will be briefly discussed.


2014 ◽  
Vol 4 (4) ◽  
pp. 288-297
Author(s):  
LING Guiying ◽  
LI Li ◽  
GAO Jiuxiang ◽  
YU Haining ◽  
WANG Yipeng ◽  
...  

2017 ◽  
Vol 24 (7) ◽  
pp. 654-672 ◽  
Author(s):  
Malgorzata Anna Dawgul ◽  
Katarzyna E. Greber ◽  
Wieslaw Sawicki ◽  
Wojciech Kamysz

Sign in / Sign up

Export Citation Format

Share Document